Friday, 19 Oct 2018

You are here

The RheumNow Week in Review - 15 December 2017

Dr. Jack Cush reviews the news from the past week on RheumNow.com. Subscribe to the podcast on iTunes and SoundCloud.com. 

  1. NICE and NHS reject the approval of Tocilizumab for use in GCA citing cost concerns https://t.co/TZMmnj91sp https://t.co/aQMFLKVCYo
  2. Another TNFi biosimilar FDA approved yesterday! This time its Pfizers Ixifi (infliximab-qbtx) becomes the 3rd remicade biosimilar (Inflectra, Renflexis) and the 6th TNFi biosimilar (in addition to Erelzi, Amjevita, Cyltezo) to be FDA approved in 20 mos. https://buff.ly/2C2fWcl
  3. 240 pts with FUO or inflammation unknown origin (IUO) studied w/ FDG-PET = helpful in Dx of >50% of pts. 190 pts (79.2%) were dx by FDG-PET (Still’s, Lg vessel vasculitis, PMR, IgG4 most common) FDG-PET/CT most helpful with age >50, CRP >30 mg/L & no fever https://buff.ly/2nQcPSK
  4. Small pilot, controlled, delayed Rx trial of 20 PM/DM pts showed at 3 mos,  50% of Abatacept, but only 11% of control/delayed Rx pts responded to therapy.  At 6 mos, with all on ABA, 8/19 responded.  ABA has potential and merits further study in PM/DM  https://buff.ly/2B4ezgg
  5. Data presented at American Society of Hematology mtg shows that Abatacept treatment decreases GVHD 32% to 2%  in patients receiving hematopoietic stem cell transplants Rx for advanced cancer & other blood disorders https://buff.ly/2kTlmDe
  6. C4d may be useful in monitoring SLE. C4d PPV 68% for high Dz activty, correlates w/ SLEDAI w/ higer Dz activity & C4d w/ dsDNA 5 fold better ability to predict lupus nephritis. https://t.co/LpUuAaqUWl
  7. 611 Finnish DMARD NAIVE, Early RA pts (71% RF+) treated with DMARDs, Triple Rx - 68% and 75% achieve DAS28-3 remission at 3 mos and 6 mos respectively. Hence higher response rates with earlier Dx and Rx! https://t.co/iWBs5vhxc7
  8. Similarities were found between Feltys syndrome and LGL leukemia - in both 40% have somatic STAT3 mutations, expansion of CD8+ T cells, same cytokine profile and STAT3 activation  https://buff.ly/2nOLZdB
  9. Febuxostat Works in Early Gout But Fails to Protect from Xray Damage
  10. FDA Approves Mepolizumab for Churg-Strauss (EGPA)
  11. Offspring of RA Women Have Higher Risk of RA and Other Diseases 

 

 

Disclosures: 
The author has received compensation as an advisor or consultant on this subject

Add new comment

More Like This

RheumNow Week in Review – ACR Preview Edition (10.19.18)

Dr. Jack Cush summarizes the news and reports from RheumNow.Com this past week and previews RheumNow activities at the upcoming ACR 2018 meeting in Chicago.

RheumNow Week in Review – Four Fingers are Best (10.12.18)

Dr. Jack Cush reviews the news and journal reports from the past week on RheumNow.com. New info on scleroderma-SLE overlap, nailfold capillaroscopy, Women with SpA, acute gout management and lupus patient in pain who visit the ED.

RheumNow Week in Review – Vitamin D Falls Again (10.4.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com. 

RheumNow Week in Review – I Wanna New Drug (9.28.18)

Dr. Jack Cush reviews the news from the past week on RheumNow.com, including news on inappropriate opioids, pre-clinical RA treatment, DMARDs in Gout, the decline of arthroscopy, and a pain in the mouth.

CDC: 2017 Record Number of Influenza Deaths

The CDC reports that in 2017, influenza killed and hospitalized more people in the United States than any other year in the last few decades. (Citation Source http://bit.ly/2DBr0TE)